Clinical trials: Prolactinomas
Prolactinoma, Insulin Resistance
Insulin Resistance in Women With Prolactinoma
Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.
- Conditions
- Prolactinoma, Insulin Resistance, Hyperlipidemia
- Trial name
- NCT00481299
- Where
- Brazil
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Prolactinoma
Exercise Capacity and Physical Activity Level in Prolactinoma Patients
Prolactinoma, one of the most common pituitary adenomas, is an adenoma that causes excessive prolactin (PRL) secretion. An increase in prolactin level can cause weakness, decrease in muscle mass and fatigue.
- Trial name
- NCT05236829
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Pituitary Neoplasm, Pituitary Adenoma
Rhinological Outcomes in Endonasal Pituitary Surgery
This is a prospective, multi-center observational study designed to address patient-reported nasal outcomes in adults undergoing endoscopic and microscopic surgical removal of pituitary tumors.
- Conditions
- Pituitary Neoplasm, Pituitary Adenoma, Prolactinoma, Cushings Disease
- Trial name
- NCT01504399
- Where
- 4 sites in United States
- Volunteers
- 235 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Prolactinoma
Study on Therapy of Non-invasive Prolactinoma
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
- Trial name
- TNAPA (NCT03353025)
- Testing
- transsphenoidal surgery treatment, dopamine agonist treatment
- Where
- China
- Volunteers
- 394 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Resistance, Disease, Prolactinoma
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas
- Trial name
- NCT03400865
- Testing
- HCQ/CQ and CAB combined treatment
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhebao Wu
Prolactinoma, Prolactin Excess
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve.
- Trial name
- SPARAGMOS (NCT07463235)
- Testing
- Cabergoline
- Where
- 16 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Prolactinoma
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral…
- Trial name
- ProBOLIC (NCT07045935)
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Hypogonadotropic Hypogonadism, Prolactinoma
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary…
- Trial name
- NCT00697814
- Testing
- Clomiphene citrate
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Federal University of São Paulo
Prolactinomas
Cardiac Valve Complications in Prolactinomas Treated With Cabergoline
Dopamine agonists are first-line agents for the treatment of prolactinomas (1) and Parkinson's disease (2). There is evidence supporting a causal relationship between the occurrence of drug-induced "restrictive" valvular heart…
- Trial name
- ValveCab (NCT00460616)
- Testing
- Cabergoline
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federico II University
Prolactinoma, Prolactin-Producing Pituitary Tumor
PRolaCT - Three Prolactinoma RCTs
This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (>2 years) period of pretreatment…
- Trial name
- NCT04107480
- Testing
- Endoscopic trans-sphenoidal adenoma resection, Dopamine Agonists
- Where
- 3 sites in Netherlands
- Volunteers
- 880 people
- Sponsor
- Leiden University Medical Center
Non-functioning Pituitary Adenomas, Prolactinomas
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery.
- Trial name
- NCT01620138
- Testing
- Pasireotide, cabergoline
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Pituitary Neoplasms, Prolactinoma
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
The purpose of this research study is to determine the utility of educational materials designed to inform patients of their pituitary condition, in an effort to assist the patients, families, and staff deal with pituitary…
- Conditions
- Pituitary Neoplasms, Prolactinoma, ACTH-Secreting Pituitary Adenoma, Gigantism
- Trial name
- NCT01775332
- Testing
- Educational Intervention
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Hyperprolactinoma
Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients
Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline.
- Trial name
- NCT01344291
- Testing
- Curcumin
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Mashhad University of Medical Sciences
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Macroprolactinoma
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
To study the effects of rapid escalation of Cabergoline in comparison to conventional dosing in macroprolactinomas. Rapid escalation of cabergoline may help in earlier normalization of prolactin and shrinkage of tumor mass, and…
- Trial name
- NCT01143584
- Testing
- Cabergoline
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Invasive Pituitary Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601289
- Testing
- temozolomide, DNA methylation analysis, microarray analysis
- Sponsor
- Jonsson Comprehensive Cancer Center
Invasive Prolactinomas Involving the Cavernous Sinus
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
The purpose of this study is to observe whether dopamine agonists can be safely withdrawn after the tumor volume and prolactin level of invasive prolactinomas involving the cavernous sinus have been effectively controlled through…
- Trial name
- NCT02536261
- Where
- 8 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhebao Wu